Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.35M P/E - EPS this Y 61.70% Ern Qtrly Grth -
Income -31.41M Forward P/E -1.95 EPS next Y 8.20% 50D Avg Chg -15.00%
Sales 675k PEG - EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -59.00%
Recommedations 2.00 Quick Ratio 0.55 Shares Outstanding 34.76M 52W Low Chg 193.00%
Insider Own 18.40% ROA -152.67% Shares Float 13.74M Beta 2.65
Inst Own 49.18% ROE - Shares Shorted/Prior 256.78K/35.04K Price 1.17
Gross Margin 100.00% Profit Margin - Avg. Volume 182,351 Target Price 5.30
Oper. Margin -3,077.63% Earnings Date - Volume 52,112 Change 0.86%
About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc. News
04/10/24 Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
03/28/24 Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
03/25/24 Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
03/14/24 Unicycive Announces $50 Million Private Placement
03/13/24 Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
03/07/24 Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
03/04/24 Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
02/14/24 Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
02/06/24 We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
01/29/24 Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
01/24/24 Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
07:03 AM Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
12/18/23 Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
11/29/23 Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
11/17/23 Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)
11/14/23 Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
06:03 AM Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
09/06/23 Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
08/29/23 Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
08/17/23 Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
UNCY Chatroom

User Image Zstock2020 Posted - 1 day ago

$UNCY isn’t the problem here that they only have money for 1-2 quarters left? I don’t see that they raised recently?

User Image pazzaaaaaa Posted - 4 days ago

$UNCY Just saw the CEOs company update/presentation. He didn’t release any data but he’s very excited for the data coming out soon on their current trials. This stock is a sleeping giant and could easily hit the 4-5$ range in a day on good data.

User Image MKRReformed Posted - 4 days ago

$uncy massive candle 👀

User Image ICU2025 Posted - 5 days ago

$UNCY looks like nothing came out of the speech this morning, probably means under $1 incoming. When are results for last phase expected.

User Image Earth4thewin Posted - 5 days ago

$UNCY analysts are setting price targets between $3 to $9 on $UNCY . 🤷

User Image pazzaaaaaa Posted - 5 days ago

$UNCY Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m. ET. Finally found a nice floor at 1.05-1.10 right before a company update tomorrow. Lots of volume this past week. Somethings brewing…

User Image Americanbulls Posted - 5 days ago

$UNCY the bull pattern is confirmed & a BUY signal is issued @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=UNCY. Buy Level: 1.14 Target: 2.97

User Image ICU2025 Posted - 1 week ago

$UNCY it’s very easy for firms and M Ms to manipulate these small stocks. Until revenue is streaming in I think you trade it vs holding. I will buy again under $1.00 and hold for run on the data results in June

User Image reces1 Posted - 1 week ago

$UNCY Just a brutal takedown the last two weeks. Free fall.

User Image ICU2025 Posted - 1 week ago

$RMTI $DVA will buy us sooner than later Who ends up with $ICU and $UNCY Is the big question? What a great and interesting 24 months are ahead for us.

User Image pazzaaaaaa Posted - 1 week ago

$UNCY CEO will present company update next. Doubt he’s gonna present bad news at a conference, very bullish

User Image iLikeMyUsername Posted - 1 week ago

$UNCY

User Image TragicTwits Posted - 1 week ago

$UNCY added some more $1.30

User Image pazzaaaaaa Posted - 1 week ago

$UNCY it’s so obviously being brought down by someone who wants cheaper prices. Down 15% since a 9$ price target was announced and trading at a 40million market cap while they have 50 million just in cash among other things like patents worth a lot. Interesting…

User Image Stock_Titan Posted - 1 week ago

$UNCY Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference https://www.stocktitan.net/news/UNCY/unicycive-therapeutics-to-present-at-the-noble-capital-markets-4i95t5wrqj36.html

User Image reces1 Posted - 2 weeks ago

$UNCY Hmmm.

User Image WagTwits Posted - 2 weeks ago

$UNCY undervalued

User Image reces1 Posted - 2 weeks ago

$UNCY Going to keep waiting on entry. Unlimited hidden shares at $1.41. Not letting it run.

User Image pazzaaaaaa Posted - 2 weeks ago

$UNCY insane that this stock is trading at 1.40$/50Mil market cap when they have 50Mil in cash. Very good data already and massive upside potential waiting for more data which is coming very soon with multiple buy ratings ranging from 5-12$. New buy ratings and bullish price targets coming in every month. Worried about bad data coming in? Sure but look at the risk to reward ratio. Good data will boost this to 10-12$ easily which is 6-8x from here. Bad data which isn’t very likely at this point will obviously ruing the company but I’m willing to take this risk for a 6-8x.

User Image Walter100 Posted - 2 weeks ago

$UNCY From X:

User Image newandimproveddonkeykong Posted - 2 weeks ago

@Jeffkad @Elvis50 Piper Sandler has to eat too....Spectrum was doing safety trials on this drug in 2013. FDA already kicked it back once and asked for more data. There are plenty of binders out there, some generic, government is a big payer and Renazorb's angle is pill burden. Sevelamer + Tenapanor has already had a real study (multiple ones). Millions of patients have used sevelamer, tens of thousands have used tena for IBS, thousands have gone through trials with Tenapanor for hyperphos.... The FDA isn't just there to just rubber stamp trials. They actively guide healthcare and care pathways through approvals. Why move Renazorb along quickly now after more than a decade? Maybe something happens with $UNCY, but my bet is that spend the most recent 50 million they raised like they spent the last 50 million they raised and maybe they get a PDUFA date. Maybe they get an approval.

User Image newandimproveddonkeykong Posted - 2 weeks ago

@Quantumup @cash You guys keep posting $UNCY on $ARDX side, so here's what I know about them. Renazorb is an orphan drug bought from spectrum back in 2018. A bioequivalence trial was completed in 2022 and the FDA kicked back the NDA for more data. Fast forward 5 quarters and here we are, waiting for an NDA submission for ANOTHER phosphate binder from $UNCY. Cross posting is part of the game, but come on. UNCY is working on a better VHS recorder two quarters after digital came on the market.

User Image Quantumup Posted - 2 weeks ago

Piper Sandler🏁 $UNCY OW/$9~says "OLC Is Small But Mighty Just Like This Microcap Name" Views $UNCY trading@cash=sig below its value, but thinks has major upside ahead of OLC approval. Notes CKD=MEGA mkt w/ >500K on kidney dialysis (80%=phosphate binders)=$2.5B WW in '21. $ARDX

User Image Thestocktraderhubzee Posted - 2 weeks ago

$UNCY Piper Sandler Initiates Coverage On Unicycive Therapeutics with Overweight Rating, Announces Price Target of $9

User Image WagTwits Posted - 2 weeks ago

$UNCY

User Image TragicTwits Posted - 2 weeks ago

$UNCY at my average again. Jump in here 🤣 @pocketmoney

User Image BioTekk Posted - 2 weeks ago

$ARDX Could $UNCY be threat to $ARDX? ? If not, why?

User Image WagTwits Posted - 2 weeks ago

$UNCY holding https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-unicycive-therapeutics-amidst-positive-milestones-and-solid-financial-footing?utm_source=alphanewsstream.com&utm_medium=referral

User Image Walter100 Posted - 3 weeks ago

$UNCY

User Image WagTwits Posted - 3 weeks ago

$UNCY

Analyst Ratings
Benchmark Speculative Buy Apr 15, 24
Piper Sandler Overweight Apr 4, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 14, 24
HC Wainwright & Co. Buy Mar 8, 24
HC Wainwright & Co. Buy Mar 5, 24
Noble Capital Markets Outperform Feb 14, 24
HC Wainwright & Co. Buy Dec 19, 23
Benchmark Speculative Buy Dec 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schiller Brigitte Director Director May 16 Buy 0.825 15,000 12,375 15,000 05/17/22